Sun Pharma, Israeli Institute Tie Up For Cancer Drug Development

 

Indian drug maker Sun Pharmaceutical Industries said on Wednesday (15 April) that it has entered into an exclusive worldwide research and license agreement with the Israel institute of technology--- Technion, aiming at the development of a collaborative research project. 

 

The joint project, based on new findings by Nobel prize laureate  Aaron Ciechanover and his team, that can potentially lead to the development of novel anti-cancer drugs. 

  

“We are very excited about this new endeavor between Sun Pharma, with the Technion. We are confident that this collaboration will help us move rapidly forward with our research” said Ciechanover, in a media statement. 

 

"We explored several collaboration alternatives, but Sun Pharma’s market leadership and its long term commitment have made this collaboration a very high priority for us," he added. 

 

“This collaboration is part of the various initiatives that Sun Pharma is taking to enhance its specialty pipeline. Mutually beneficial partnerships with independent research institutes, especially world renowned institutes, such as the Technion, is our preferred route to bring to the market, innovative products for unmet medical needs” said Kirti Ganorkar, senior vice President, business development, at Sun Pharma.